South San Francisco–based Soley Therapeutics has announced the close of a $200 million Series C financing to advance its proprietary cell stress sensing platform and bring its first oncology programs into clinical development. The new capital will support IND-enabling work and early clinical trials for two internally discovered cancer assets, including a lead program for acute myeloid leukemia that is expected to file an IND in 2026, and a second program targeting solid tumors.

The round was led by Surveyor Capital, a Citadel company, with participation from new investors HRTG Partners and RWN Management. Existing backers also joined the round, including Breyer Capital, Doug Leone Family Fund, and GordonMD Global Investments, along with other undisclosed investors.

Soley’s technology platform captures time-based cellular stress responses across thousands of features in human cells and converts this data into structured signatures using proprietary computer vision and AI models. The system allows the company to screen hundreds of thousands of compounds each week and generate reproducible data at scale through in-house automation and robotics, accelerating discovery and drug design.

According to co-founder and CEO Yerem Yeghiazarians, the company was built to directly observe how living human cells respond to drugs and translate those insights into new medicines. He noted that the strong backing from life sciences and technology-focused investors validates Soley’s approach as it moves its lead programs into the clinic and continues to expand its platform and pipeline.

Beyond oncology, Soley plans to use the new funding to progress stress-modulating drug candidates for neurodegenerative and metabolic diseases and to further scale its discovery platform. The company also leverages full-stack AI infrastructure through its collaboration with Oracle and NVIDIA to support its research and development efforts.

OpenAI has acquired US health-tech startup Torch for more than USD 100 million. The acquisition brings Torch into OpenAI’s growing healthcare efforts, including its recently launched ChatGPT Health feature.

Torch has been building a product that helps users bring scattered medical records into one place and use AI to better understand them. OpenAI said Torch’s work fits closely with ChatGPT Health, which lets users upload health data and talk to the chatbot about test results, appointments, diet, and workouts.

OpenAI said privacy will remain a priority. The company has committed that health data and conversations inside ChatGPT Health will stay private and will not be used to train its core AI models. Torch’s leadership team and employees are expected to join OpenAI as part of the deal.

Torch was founded in January 2025 and focuses on helping people make sense of their medical information using AI. The company serves individuals who want a clearer view of their health data and how it connects across hospitals, labs, and devices. It operates in the United States.

Moxie Beauty raised USD 15 million in a Series A round. Bessemer Venture Partners led the round. They invested because most Indians have textured hair. Yet many products on the market do not fit those needs well. The category has seen fast growth in recent years. Moxie makes haircare items suited for Indian hair types and weather.

The brand offers shampoos, conditioners, serums, and styling tools like brushes and wax sticks. Some products are new to the Indian market. Bessemer said they are proud to lead the round. They are excited to work with co-founders Nikita Khanna and Anmol Ahlawat.

Moxie Beauty is a haircare brand. It develops and sells products for textured hair. The company serves consumers in India.

PsiThera raised $47.5 million in Series A financing. Samsara Biocapital and Lightstone Ventures led the equity round. Other investors include Roivant, YK Bioventures, Eurofarma Ventures, and more. The company came from a Roivant spinout and now runs independently.

Eric Shaff started as CEO. He brings experience from Seres Therapeutics. The leadership also has Woody Sherman as Founder and Chief Innovation Officer, and Camil Sayegh as Chief Scientific Officer.

The funding advances a pipeline of oral drugs for immune and inflammatory diseases. It starts with TNF superfamily programs. The company uses its QUAISAR platform with molecular dynamics and AI to model proteins and drugs.

Investors like the setup. Christina Isacson from Lightstone Ventures, now board chair, said it mixes computation and science well for tough targets. Eric Shaff said the platform sped their lead program from hit to optimization in four months. Woody Sherman said it beats limits of old methods on moving molecules.

PsiThera makes oral drugs for immune and inflammatory diseases. It uses biophysics, AI modeling, and biology to hit targets once limited to injectables. The pipeline targets TNF superfamily members for patients with those conditions.

SimpleClosure, founded in 2023, has raised just over $20 million from investors including Infinity Ventures, TTV Capital, Anthemis, The LegalTech Fund, and Carta. The company's founder and CEO, Dori Yona, came up with the concept after experiencing the complexity of shutting down a company.

SimpleClosure is expanding its vision with the launch of Asset Hub, a marketplace designed to help founders recover value from their assets, such as source code, operational data, domain names, and equipment.

According to Yona, the company has seen strong year-over-year growth in startup shutdown activity, with 2.6x more companies closing in Q1 2026 compared to Q1 2025. The Asset Hub aims to capture the value of these assets, which often evaporate during the shutdown process.

X-energy has raised over $1 billion in capital investment through its IPO and a simultaneous private investment.

This funding will be used to hasten the placement of its Xe-100 advanced small modular reactors as the world searches for clean, sustainable baseload power.

The Xe-100 reactor utilises "pebbles", graphite spheres containing thousands of "TRISO" particles, which are essentially indestructible and capable of withstanding high temperatures.

X-energy intends to use the proceeds to fund the final stages of licensing, supply chain development, and the construction of its TRISO-X fuel fabrication facility.

The company is currently managing a pipeline of over 11 gigawatts of new nuclear capacity through various commercial partnerships, including a project with Dow Inc. to provide high-temperature steam and power for industrial processes.

Cloneable, a startup that uses AI to shadow human experts in heavy industries such as energy and replicate their specialized workflows into autonomous agents, has raised $4.6 million in seed funding. Congruent Ventures led the raise, which included participation from First In, Overline, Bull City Venture Partners, and St. Elmo Venture Capital.

The idea for Cloneable traces back to a bottleneck its founders encountered years earlier while working in the field. The startup's founders realized that heavy industries face a “knowledge crisis” as experienced workers retire faster than they can be replaced.

Cloneable aims to capture and preserve that kind of institutional knowledge. The funding will also support expansion into infrastructure-heavy industries such as public utilities, vegetation management, construction, rail, mining, agriculture, and manufacturing.

The company claims that a process that typically takes a human engineer eight hours can be completed by a Cloneable agent in under two minutes.